Interaktionen zwischen dem Peptidhormon Relaxin und dem humanen Glukokortikoidrezeptor Michael Peter Greinwald11.111.1.121.1.23361#3191.1.34345#2151.1.451.1.5671.1.681.1.71.1.7.191.1.7.21.1.7.31.1.7.4101.1.7.5111.1.7.6121.1.7.71.1.7.8131.21.2.114355#4171.2.2151.2.31617587#520181.2.4191.2.5201.2.621377#2221.3222222.12.1.1232.1.22.1.32.1.3.1242.1.3.22.1.42.22.2.12.2.1.1252.2.1.226272.2.22.2.2.12.2.2.2282.2.2.32.2.2.4292.2.2.52.2.2.6302.2.2.7312.2.32.2.3.12.2.3.2322.2.3.32.2.3.4332.2.3.52.32.3.1342.3.22.42.4.1352.4.22.4.336372.4.438392.4.5402.52.5.12.5.2412.62.6.1266#2892.6.2422.72.7.143302#20844547#4382.7.2551#434454647293#7448487#682.7.349543#451502.7.4512.82.8.12.8.2522.8.3532.8.4542.8.52.8.62.955563563.157585#43458586#473586#473586#47459586#474586#47360586#4733.261479#2273.3623.3.163580#1743.3.2544#1413.464586#44965586#470586#50666588#4353.567504#47768585#42869586#43170587#439589#4393.67172459#264585#42973461#271590#4333.6.13.774577#46275577#46276476774.1784.279804.3814.4824.54.5.14.5.2834.5.384854.5.4864.6874.788894.7.14.7.1.190914.7.1.24.892592AbkürzungsverzeichnisLiteraturverzeichnisDanksagungLebenslaufEidesstattliche ErklärungdeInhaltsverzeichnisHilfe Literaturverzeichnis 1. Almawi W. Y., Melemedjian O. K.: Molecular mechanisms of glucocorticoid antiproliferative e f fects: antagonism of transcription factor activity by glucocorticoid receptor. J. Leukoc. Biol. 2002, 71, S. 9-15. 2. Bani D., Ballati L., Masini E., Bigazzi M. and Sacchi T. B.: Relaxin counte r acts asthma-like reaction induced by inhaled antigen in sensitized guinea pigs. Endocrinology. 1997, 138, S. 1909–1915. 3. Bani D., Masini E., Bello M. G., Bigazzi M. and Sacchi T. B.: Relaxin act i vates the L-arginine-nitric oxide pathway in human breast cancer cells. Cancer Res. 1995a, 55, S. 5272–5275. 4. Bani D., Bigazzi M., Masini E., Bani G. and Sacchi T. B.: Relaxin depresses platelet aggregation: in vitro studies on isolated human and rabbit platelets. Lab. Invest. 1995b, 73, S. 709–716. 5. Bani D., Maurizi M. and Bigazzi M.: Relaxin reduces the number of circulating platelets and d e presses platelet release from megakaryocytes: studies in rats. Platelets. 1995c, 6, S. 330– 335. 6. Bani D., Failli P., Bello M. G., Thiemermann C., Bani Sacchi T., Bigazzi M. et al.: Relaxin activates the L-argininenitric oxide pathway in vascular smooth muscle cells in culture. Hypertension. 1998a, 31, S. 1240–1247. 7. Bani D., Masini E., Bello M. G., Bigazzi M. and Sacchi T. B.: Relaxin pr o tects against myocardial injury caused by ischemia and reperfusion in rat heart. Am. J. Pathol. 1998b, 152, S. 1367–1376. 8. Bani D., Nistri S., Quattrone S., Bigazzi M. and Bani Sacchi T.: The vasor e laxant hormone relaxin induces changes in liver sinusoid microcirculation: a morphologic study in the rat. J. Endocrinol. 2001, 171, S. 541–549. 9. Bani D.: Relaxin: a pleiotropic hormone. Gen. Pharmacol. 1997a, 28, S. 13-22. 10. Bani D.: Relaxin and breast cancer. Bull. Cancer. 1997b, 84, S. 179–182. 11. Bani G., Bigazzi M. and Bani D.: Effects of relaxin on the mouse mammary gland. I. The myoepith e lial cells. J. Endocrinol. Invest. 1985, 8, S. 207–215. 12. Bani G., Bigazzi M. and Bani D.: The effects of relaxin on the mouse mammary gland. II. The ep i thelium. J. Endocrinol. Invest. 1986, 9, S. 145–152. 13. Bani-Sacchi T., Bigazzi M., Bani D., Mannaioni P. F. and Masini E.: Relaxin-induced increased coronary flow through stimulation of nitric oxide produ c tion. Br. J. Pharmacol. 1995, 116, S. 1589-94. 14. Bartsch O., Bartlick B., Ivell R.: Relaxin signalling links tyrosine phosphorylation to phosphod i esterase and adenylyl cyclase activity. Mol. Hum. Reprod. 2001a, 7, S. 799–809 15. Bartsch O., et al.: Relaxin signal transduction couples tyrosine phosphorylation to cAMP upregul a tion. In Relaxin 2000 (Tregear, G.W. et al., eds) Kluwer Academic Publishers. 2001b, S. 309–316. 16. Bathgate R. A. D., Samuel C. S., Burazin T. C. D., Layfield S., Claasz A. A., Reytomas I. G. T. et al.: Human relaxin gene 3 (H3) and the equivalent mouse relaxin (M3) gene: novel members of the r e laxin peptide family. J. Biol. Chem. 2001, 277, S. 1148-1157. 17. BD Biosciences Clontech: pGRE-Luc Vector Information. 2002 18. Bellingham D. L., Sar M., Cidlowski J. A.: Ligand-dependent down-regulation of stably transfected human glucocorticoid receptors is assoc i ated with loss of functional glucocorticoid responsiveness. Mol. Endocrinol. 1992, 6, S. 2090–2102. 19. Bianchi S., Bani G. and Bigazzi M.: Effects of relaxin on the mouse ma m mary gland. III. The fat pad. J. Endocrinol. Invest. 1986, 9, S. 153–160. 20. Bigazzi M., Brandi M. L., Bani G. and Sacchi T. B.: Relaxin influences the growth of MCF-7 breast cancer cells. Mitogenic and antimitogenic action depends on peptide concentration. Cancer. 1992, 70, S. 639–643. 21. Bigazzi M., Del Mese A., Petrucci F., Casali R. and Novelli G. P.: The local administration of relaxin induces changes in the microcirculation of the rat mesocaecum. Acta Endocrinol. 1986, 112, S. 296–299. 22. Bigazzi M., Nardi E., Bruni P. and Petrucci F.: Relaxin in human decidua. J. Clin. Endocrinol. Metab. 1980, 51, S. 939-941. 23. Blundell T. L. and Humbel R. E.: Hormone families: pancreatic hormones and homologues growth factors. Nature. 1980, 287, S. 781-787. 24. Bodwell J. E., Hu J. M., Orti E., Munck A.: Hormone-induced hyperpho s phorylation of specific phosphorylated sites in the mouse glucocorticoid r e ceptor. J Steroid Biochem Mol Biol. 1995, 52, S. 135–40. 25. Bortz J, Lienert G. A., Boehnke K.: Verteilungsfreie Methoden in der Biost a tistik. Springer Verlag. 1990 26. Bray P. J., Du B., Mejia V. M., Hao S. C., Deutsch E., Fu C., Wilson R. C., Hanauske-Abel H., McCaffrey T. A.: Glucocorticoid resistance caused by reduced expression of the glucocorticoid r e ceptor in cells from human va s cular lesions. Arterioscler Thromb Vasc Biol. 1999, 19, S. 1180-9. 27. Bronnegard M.: Steroid receptor number. Individual variation and downreg u lation by treatment. Am. J. Respir. Crit. Care Med. 1996, 154, S. S28–S33. 28. Bryant-Greenwood G. D. and Schwabe C.: Human relaxins: chemistry and biology. Endocrine Rev. 1994, 15, S. 5-26. 29. Bullesbach EE, Schwabe C.: Functional importance of the A chain loop in relaxin and insulin. J Biol Chem. 1994, 269, S. 13124-8. 30. Burnstein K. L., Bellingham D. L., Jewell C. M., Powell-Oliver F. E., and Cidlowski J. A.: Aut o regulation of glucocorticoid receptor gene expression. Steroids. 1991, 56, S. 52–58. 31. Cadepond F., Ulmann A., Baulieu E. E.: RU486 (mifepristone): mechanisms of action and clinical uses. Annu Rev Med. 1997, 48, S. 129-56. 32. Cidlowski J. A., Cidlowski N. B.: Regulation of glucocorticoid receptors by glucocorticoids in cu l tured HeLa S3 cells. Endocrinology. 1981, 109, S. 1975-82. 33. Danielson L. A., Sherwood O. D. and Conrad K. P.: Relaxin is a potent renal vasodilator in co n scious rats. J. Clin. Invest. 1999, 103, S. 525–533. 34. Dao-Phan H. P., Formstecher P., Lefebvre P.: Disruption of the glucocort i coid receptor assembly with heat shock protein 90 by a peptidic antigluc o corticoid. Mol. Endocrinol. 1997, 11, S. 962–972. 35. Dayanithi G., Cazalis M. and Nordmann J. J.: Relaxin affects the release of oxytocin and vasopressin from the neurohypophysis. Nature. 1987, 325, S. 813–816. 36. Dschietzig T., Bartsch C., Richter C., Laule M., Baumann G., Stangl K.: Relaxin, a pregnancy ho r mone, is a functional endothelin-1 antagonist: a t tenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factor-kappaB. Circ Res. 2003, 92, S. 32-40. 37. Dschietzig T., Richter C., Bartsch C., Laule M., Armbruster F. P., Baumann G. et al.: The pregnancy hormone relaxin is a player in human heart failure. FASEB J. 2001, 15, S. 2187–2195. 38. Dschietzig T., Stangl K.: Relaxin: a pregnancy hormone as central player of body fluid and circul a tion homeostasis. Cell. Mol. Life Sci. 2002, 59, S. 1–13. 39. Erikson M. S. and Unemori E. N.: Relaxin trials in systemic sclerosis. In: Proceedings of the 3rd Int. Conf. on RLX and Related Peptides (Broome, Aus.). 2000, S. 373–381. 40. Essig M., Schoenfeld C., D’Eletto R., Amelar R., Oubin L. and Steinetz B. G.: Relaxin in human seminal plasma. Ann. N. Y. Acad. Sci. 1982, 380, S. 224–230. 41. Failli P., Nistri S., Quattrone S., Mazzetti L., Bigazzi M., Bani Sacchi T. et al.: Relaxin upregulates inducible nitric oxide expression and nitric oxide generation in rat coronary endothelial cells. FASEB J. 2001, 16, S. 252–254. 42. Fevold H. L., Hisaw F. L. and Meyer R. K.: The relaxative hormone of the corpus luteum. 1st purif i cation and concentration. J. Am. Chem. Soc. 1930, 52, S. 3340-3348 43. Fields P. A., Lee A. B., Haab L. M., Hwang J. and Sherwood D.: Evidence for a dual source of r e laxin in the pregnant rat: immunolocalization in the corpora lutea and endometrium. Endocrinology. 1992, 130, S. 2985–2990. 44. Garber S. L., Mirochnik Y., Brecklin C. S., Unemori E. N., Singh A. K., Slobodskoy L. et al.: R e laxin decreases renal interstitial fibrosis and slows progression of renal disease. Kidney Int. 2001, 59, S. 876–882. 45. Gehring U., Mugele K., and Ulrich J.: Cellular receptor levels and glucocort i coid responsiveness of lymphoma cells. Mol. Cell. Endocrinol. 1984, 36, S. 107–113. 46. Graham E. F. and Dracy A. E.: The effect of relaxin and mechanical dilat a tion of the bovine cervix. J. Dairy Sci. 1953, 36, S. 772-777. 47. Green B., Leake R. E.: Steroid hormone receptors: Assay and characteriz a tion. Steroid hormones: a practical approach; IRL Press. 1987, S. 67-98. 48. Gunnersen J. M., Fu P., Roche P. J. and Tregear G. W.: Expression of human relaxin genes: chara c terization of a novel alternatively-spliced human relaxin mRNA species. Mol. Cell. Endocrinol. 1996, 118, S. 85-94. 49. Hamolsky M. and Sparrow R. C.: Influence of relaxin on mammary development in sexually imm a ture female rats. Proc. Soc. Exp. Biol. Med. 1945, 60, S. 8-9. 50. Hansell D. J., Bryant-Greenwood G. D. and Greenwood F. C.: Expression of the human relaxin H1 in the decidua, trophoblast, and prostate. J. Clin. Endocrinol. Metab. 1991, 72, S. 899–904. 51. Hisaw F. L.: Experimental relaxation of the pubic ligament of guinea pigs. Proc. Soc. Exp. Biol. Med. 1926, 23, S. 661-663. 52. Holm S.: A simple sequentially rejective multiple test procedure. Scand. J. Stat. 1979, 6, S. 65-70. 53. Hsu S. Y., Nakabayashi K., Nishi S., Kumagai J., Kudo M., Sherwood O. D. et al.: Activation of o r phan receptors by the hormone relaxin. Science. 2002, 295, S. 671–674. 54. Hudson P., Haley J., John M., Cronk M., Crawford R., Haralambidis J. et al.: Structure of a genomic clone encoding biologically active human relaxin. Nature. 1983, 301, S. 628-631. 55. Hudson P., John M., Crawford R., Haralambidis J., Scanlon D., Gorman J. et al.: Relaxin gene e x pression in human ovaries and the predicted structure of a human prorelaxin by analysis of cDNA clones. EMBO J. 1984, 3, S. 2333-2339. 56. Ivell R, Einspanier A.: Relaxin peptides are new global players. Trends Endocrinol Metab. 2002, 13, S. 343- 8. 57. Jenkins B. D., Pullen C. B., Darimont B. D.: Novel glucocorticoid receptor coactivator effector mechanisms. Trends Endocrinol. Metab. 2001, 12, S. 122-6. 58. Jordan V. C.: Selective estrogen receptor modulation: a personal perspe c tive. Cancer Res. 2001, 61, S. 5683-7. 59. Kakouris H., Eddie L. W. and Summers R. J.: Cardiac effects of relaxin in rats. Lancet. 1992, 339, S. 1076–1078. 60. Katzenellenbogen, J. A.; Katzenellenbogen, B. S.: Nuclear hormonereceptors: ligand-activated reg u lators of transcription and diverse cell responses. Chem. Biol. 1996, 3, S. 529-536. 61. Kenyon N. J., Ward R. W., Last J. A.: Airway fibrosis in a mouse model of airway inflammation. Toxicol. Appl. Pharmacol. 2003, 186, S. 90–100. 62. Kliewer S. A., Moore J. T., Wade L., Staudinger J. L., Watson M. A., Jones S. A., McKee D. D., Oliver B. B., Willson T. M., Zetterstrom R. H., Perlmann T., Lehmann J. M.: An orphan nuclear r e ceptor activated by pregnanes d e fines a novel steroid signaling pathway. Cell. 1998, 92, S. 73-82. 63. Kraichely D. M., Sun J., Katzenellenbogen J. A., Katzenellenbogen B. S.: Conformational changes and coactivator recruitment by novel ligands for e s trogen receptor-alpha and estrogen receptor-beta: correlations with biological character and distinct differences among SRC coactivator family me m bers. Endocrinology. 2000, 141, S. 3534-45. 64. Krantz J. C., Bryant H. H. and Carr C. J.: The action of aqueous corpus l u teum extract upon uterine activity. Surg. Gynecol. Obstet. 1950, 90, S. 372-375. 65. Kumar R., Thompson E. B.: The structure of the nuclear hormone receptors. Steroids. 1999, 64, S. 310–9. 66. Laemmli U. K.: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970, 227, S. 680-685. 67. Link J. T., Sorensen B. K., Patel J., Emery M., Grynfarb M., Goos-Nilsson A.: Discovery of novel nonsteroidal glucocorticoid receptor modulators. Bioorg Med Chem Lett. 2004, 14, S. 2209-12. 68. Loke T. K., Sousa A. R., Corrigan C. J., Lee T. H.: Glucocorticoid-resistant asthma. Curr Allergy Asthma Rep. 2002, 2, S. 144-50. 69. MacLennan A. H. and Grant P.: Human relaxin. In vitro response of human and pig myometrium. J. Reprod. Med. 1991, 36, S. 630–634. 70. MacLennan A. H., Grant P. and Bryant-Greenwood G.: hRLX-1. In vitro r e sponse of human and pig myometrium. J. Reprod. Med. 1995, 40, S. 703–706. 71. MacLennan A. H., Grant P., Ness D. and Down A.: Effect of porcine relaxin and progesterone on rat, pig and human myometrial activity in vitro. J. Reprod. Med. 1986, 31, S. 43–49. 72. Marriott D., Gillece-Castro B. and Gorman C. M.: Prohormone convertase-1 will process prorelaxin, a member of the insulin family of hormones. Mol. Endocrinol. 1992, 6, S. 1441–1450. 73. Masini E., Bani D., Bigazzi M., Mannaioni P. F. and Bani-Sacchi T.: Effects of relaxin on mast cells. In vitro and in vivo studies in rats and guinea pigs. J. Clin. Invest. 199 4, 94, S. 1974– 1980. 74. Masini E., Salvemini D., Mugnai L., Bello M. G., Bani D. and Mannaioni P. F.: The effect of relaxin on myocardial ischaemia- reperfusion injury and hi s tamine release in vitro and in vivo. Inflamm. Res. 1996, 45, S. S27–S28. 75. Novak J., Danielson L. A., Kerchner L. J., Sherwood O. D., Ramirez R. J., Moalli P. A. et al.: R e laxin is essential for renal vasodilation during pre g nancy in conscious rats. J. Clin. Invest. 2001, 107, S. 1469–1475. 76. O’Byrne K. T., Eltringham L., Clarke G. and Summerlee A. J.: Effects of porcine relaxin on oxytocin release from the neurohypophysis in the anaesthetized lactating rat. J. Endocrinol. 1986, 109, S. 393–397. 77. Oakley R. H., Jewell C. M., Yudt M. R., Bofetiado D. M., Cidlowski J. A.: The dominant negative activity of the human glucocorticoid receptor beta is o form. Specificity and mechanisms of action. J. Biol. Chem. 1999, 274, S. 27857-66. 78. Oakley R. H., Sar M., Cidlowski J. A.: The human glucocorticoid receptor beta isoform. Expression, biochemical properties, and putative function. J. Biol. Chem. 1996, 271, S. 9550-9. 79. O'Dell J. R.: Therapeutic strategies for rheumatoid arthritis. N Engl J Med. 2004, 350, S. 2591-602. 80. Osborn L., Kunkel S., Nabel G.J .: Tumor necrosis factor alpha and inte r leukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc. Natl. Acad. Sci. 1989 Apr; 86, S. 2336-40. 81. Osheroff, P.L. and Phillips, H.S.: Autoradiographic localization of relaxin binding sites in rat brain. Proc. Natl. Acad. Sci. 1991, 88, S. 6413–6417. 82. Palejwala S., Stein D. S., Weiss G., Monia B. P., Tortoriello D. and Goldsmith L. T.: Relaxin pos i tively regulates matrix metalloproteinase expression in human lower uterine segment fibroblasts u s ing a tyrosine kinase signaling pathway. Endocrinology. 2001, 142, S. 3405–3413. 83. Palejwala S., Tseng L., Wojtczuk A., Weiss G., Goldsmith L. T.: Relaxin g e ne and protein expression and its regulation of procollagenase and vascular endothelial growth factor in human endometrial cells. Biol Reprod. 2002 , 66, S. 1743-8. 84. Park W. C., Jordan V. C.: Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention. Trends Mol Med. 2002, 8, S. 82-88. 85. Parry L. J., Potershi R. S., Summerlee A. J. and Jones S. A.: Mechanisms of the haemotensive action of porcine relaxin in anaesthetised rats. J. Neuroendocrinol. 1990, 2, S. 53–58. 86. Petersen L. K., Svane D., Uldbjerg N. and Forman A .: Effects of human r e laxin on isolated rat and human myometrium and uteroplacental arteries. Obstet. Gynecol. 1991, 78, S. 757–762. 87. Piccinni M. P., Bani D., Beloni L., Manuelli C., Mavilia C., Vocioni F. et al.: Relaxin favors the d e velopment of activated human T cells into Th1-like e f fectors. Eur. J. Immunol. 1999, 29, S. 2241–2247. 88. Piccinni M. P., Maggi E. and Romagnani S.: Environmental factors favoring the allergen-specific Th2 response in allergic subjects. Ann. N. Y. Acad. Sci. 2000, 917, S. 844–852. 89. Piedras-Renteria E. S., Sherwood O. D. and Best P. M.: Effects of relaxin on rat atrial myocytes. II. Increased calcium influx derived from action pote n tial prolongation. Am. J. Physiol. 1997a, 272, S. H1798–H1803. 90. Piedras-Renteria E. S., Sherwood O. D. and Best P. M.: Effects of relaxin on rat atrial myocytes. I. Inhibition of I(to) via PKA-dependent phosphoryl a tion. Am. J. Physiol. 1997b, 272, S. H1791–H1797. 91. Pujols L., Mullol J., Roca-Ferrer J., Torrego A., Xaubet A., Cidlowski J. A., Picado C.: Expression of glucocorticoid receptor alpha- and beta-isoforms in human cells and tissues. Am. J. Physiol. Cell. Physiol. 2002, 283, S. C1324-31. 92. Qin X., Garibay-Tupas J., Chua P. K., Cachola L. and Bryant- Greenwood G. D.: An autocrine/paracrine role of human decidual relaxin. I. Interstitial collagenase (matrix metallopr o teinase- 1) and tissue plasminogen activator. Biol. Reprod. 1997, 56, S. 800–811. 93. Rajapandi T., Greene L. E., Eisenberg E.: The molecular chaperones Hsp90 and Hsc70 are both ne c essary and sufficient to activate hormone binding by glucocorticoid receptor. J. Biol. Chem. 2000, 275, S. 22597-604. 94. Resche-Rigon M., Gronemeyer H.: Therapeutic potential of selective mod u lators of nuclear receptor action. Curr Opin Chem Biol. 1998, 2, S. 501-7. 95. Riad M., Mogos M., Thangathurai D., Lumb P. D.: Steroids. Curr Opin Crit Care. 2002, 8, S. 281-4. 96. Sakbun V., Ali S. M., Greenwood F. C. and Bryant-Greenwood G. D.: H u man relaxin in the amnion, chorion, decidua parietalis, basal plate, and pl a cental trophoblast by immunocytochemistry and northern analysis. J. Clin. Endocrinol. Metab. 1990, 70, S. 508-514. 97. Sambrook J., Fritsch E. F., Maniatis T.: Molecular cloning: A laboratory manual. 2nd Edition. Cold Spring Harbour Laboratory Press. 1989 98. Sanborn B. M., Kuo H. S., Weisbrodt N. W. and Sherwood O.D.: The inte r action of relaxin with the rat uterus. I. Effect on cyclic nucleotide levels and spontaneous contractile activity. Endocrinology. 1980, 106, S. 1210–1215. 99. Sapolsky R. M., Romero L. M., Munck A. U.: How do glucocorticoids infl u ence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr. Rev. 2000, 21, S. 55–89. 100. Scatchard G.: The attractions of proteins for small molecules and ions. Ann. N.Y. Acad. Sci. 1949, 51, S. 660-672. 101. Schaaf M. J., Cidlowski J. A.: Molecular mechanisms of glucocorticoid action and resistance. J. Steroid Biochem. Mol. Biol. 2002 , 83, S. 37–48. 102. Schoneveld O. J., Gaemers I. C., Lamers W.H.: Mechanisms of glucocort i coid signalling. Biochim Biophys Acta. 2004, 1680, S. 114-28. 103. Schulz M., Eggert M.: Novel ligands: fine tuning the transcriptional activity of the glucocorticoid receptor. Curr Pharm Des. 2004 , 10, S. 2817-26. 104. Schwabe C., Steinetz B. G., Weiss G., Segaloff A., McDopnald K., O’Byrne E., Hochman J. et al.: Relaxin. Rec. Prog. Horm. Res. 1978, 34, S. 123-199. 105. Seibold J. R., Korn J. H., Simms R., Clements P. J., Moreland L. W., Mayes M. D. et al.: Recomb i nant human relaxin in the treatment of scleroderma. A randomized, doubleblind, placebo-controlled trial. Ann. Intern. Med. 2000, 132, S. 871–879. 106. Sekiguchi K., Li X., Coker M., Flesch M., Barger P. M., Sivasubramanian N., Mann D. L.: Cross-regulation between the renin-angiotensin system and i n flammatory mediators in cardiac hypertrophy and failure. Cardiovasc Res. 2004 , 63, S. 433-42. 107. Seppala M, Koistinen H, Koistinen R: Glycodelins. Trends Endocrinol. Metab. 2001 , 12, S. 111-117. 108. Sherwood, O.D.: Relaxin. In: The Physiology of Reproduction, 2nd Ed. (Knobil, E. and Neill, J.D., eds) Raven Press. 1994, S. 861-1009. 109. Shishehbor M. H., Bhatt D. L.: Inflammation and atherosclerosis. Curr Atheroscler Rep. 2004, 6, S. 131-9. 110. Silva C. M., Powell-Oliver F. E., Jewell C. M., Sar M., Allgood V. E., Ci d lowski J. A.: Regulation of the human glucocorticoid receptor by long-term and chronic treatment with glucocorticoid. Steroids. 1994, 59, S. 436-42. 111. St. Louis J. and Massicotte G.: Chronic decrease of blood pressure by rat relaxin in spontaneously hypertensive rats. Life Sci. 1985, 37, S. 1351–1357. 112. Stewart D. R., Celniker A. C., Taylor C. A., Cragun J. R., Overstreet J. W. and Lasley B. L.: Relaxin in the periimplantation period. J. Clin. Endocrinol. Metab. 1990, 70, S. 1771-1773. 113. Stewart, D.R. and VandeVoort, C.A.: Relaxin secretion by human granulosa cell culture is predictive of in vitro fertilization – embryo transfer success. Hum. Reprod. 1999, 14, S. 338–344. 114. Stewart D.R., Overstreet J. W., Celniker A. C., Hess D. L., Cragun J. R., Boyers S. P., Lasley B. L .: The relationship between hCG and relaxin secr e tion in normal pregnancies vs peri-implantation spontaneous abortions. Clin. Endocrinol. 1993, 38, S. 379–385. 115. Sunder S, Lenton E. A.: Endocrinology of the periimplantation period. Baillieres Best Pract. Res. Clin. Obstet. Gynaecol. 2000, 14, S. 789-800. 116. Tashima L. S., Mazoujian G. and Bryant-Greenwood G. D.: Human relaxins in normal, benign and neoplastic breast tissue. J. Mol. Endocrinol. 1994, 12, S. 351-364. 117. Telgmann R. and Gellersen B.: Marker genes of decidualization: activation of the decidual prolactin gene. Hum. Reprod. Update. 1998, 4, S. 472–479. 118. Too C. K., Bryant-Greenwood G. D. and Greenwood F. C.: Relaxin increases the release of plasm i nogen activator, collagenase, and proteoglycanase from rat granulosa cells in vitro. Endocrinology. 1984, 115, S. 1043–1050. 119. Toth M., Taskinen P. and Ruskoaho H.: Relaxin stimulates atrial natriuretic peptide secretion in pe r fused rat heart. J. Endocrinol. 1996, 150, S. 487–495. 120. Umland S. P., Schleimer R. P., Johnston S. L.: Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. Pulm. Pharmacol. Ther. 2002, 15, S. 35-50. 121. Unemori E. N., Beck L. S., Lee W. P., Xu Y., Siegel M., Keller G. et al .: H u man relaxin decreases collagen accumulation in vivo in two rodent models of fibrosis. J. Invest. Dermatol. 1993, 101, S. 280–285. 122. Unemori E. N., Erikson M. E., Rocco S. E., Sutherland K. M., Parsell D. A., Mak J. et al.: Relaxin stimulates expression of vascular endothelial growth factor in normal human endometrial cells in v i tro and is associated with menometrorrhagia in women. Hum. Reprod. 1999, 14, S. 800–806. 123. Unemori E. N., Lewis M., Constant J., Arnold G., Grove B. H., Normand J. et al.: Relaxin induces vascular endothelial growth factor expression and angiogenesis selectively at wound sites. Wound Repair Regen. 2000, 8, S. 361–370. 124. Vasilenko P., Mead J. P. and Weidmann J. E.: Uterine growth-promoting effects of relaxin: a mo r phometric and histological analysis. Biol. Reprod. 1986, 35, S. 987–995. 125. Wallace A. D., Cidlowski J. A.: Proteasome-mediated glucocorticoid rece p tor degradation restricts transcriptional signaling by glucocorticoids. J. Biol. Chem. 2001, 276, S. 42714-21. 126. Wang-Lee J. L., Lenhart J. A., Ohleth K. M., Ryan P. L. and Bagnell C. A.: Regulation of urokinase- and tissue-type plasminogen activator by relaxin in the uterus and cervix of the prepubertal gilt. J. Reprod. Fertil. 1998, 114, S. 119–125. 127. Ward D. G., Thomas G. R. and Cronin M. J.: Relaxin increases rat heart rate by a direct action on the cardiac atrium. Biochim. Biophys. Res. Commun. 1992, 186, S. 999–1005. 128. Webster J. C., Jewell C. M., Bodwell J. E., Munck A., Sar M., Cidlowski J. A.: Mouse glucocorticoid receptor phosphorylation status influences multiple functions of the receptor protein. J. Biol. Chem. 1997, 272, S. 9287-93. 129. Wehling M.: Specific, nongenomic actions of steroid hormones. Annu Rev Physiol. 1997, 59, S. 365-93. 130. Weigel N. L., Zhang Y.: Ligand-independent activation of steroid hormone receptors. J Mol Med. 1998, 76, S. 469-79. 131. Weisinger R. S., Burns P., Eddie L. W. and Wintour E. M.: Relaxin alters the plasma osmolality-arginine vasopressin relationship in the rat. J. Endocrinol. 1993, 137, S. 505–510. 132. Wikstrom A. C., Okret S., Bakke O., Fuxe K., Gustafsson J. A.: Glucocorticoid mechanism of a c tion: monoclonal antibodies as experimental tools. Med. Oncol. Tumor Pharmacother. 1986, 3, S. 185–196. 133. Winslow J. W., Shih A., Bourell J. H., Weiss G., Reed B., Stults J. T. et al.: Human seminal relaxin is a product of the same gene as human luteal r e laxin. Endocrinology. 1990, 130, S. 2660–2668. 134. Wolfe F., Michaud K.: Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med. 2004, 116, S. 305-11. 135. Zhang Q., Liu S. H., Erikson M., Lewis M., Unemori E.: Relaxin activates the MAP kinase pathway in human endometrial stromal cells. J. Cell. Biochem. 2002, 85, S. 536–544.